Trizivir (Abacavir/Lamivudine/Zidovudine) Patent Expiration, LOE Window & CMS Spending
Trizivir (Abacavir/Lamivudine/Zidovudine) by GSK: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $139K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | GSK |
| FDA Application & Pathway | N021205 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Uncontested (0 AB Generics) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $139K |
| 2024 Medicare Part D Spend | $109K |
| 2024 Medicaid Spend | $30K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.